The rapidly emerging world of collaborations among pharma, FDA, and patient advocacy organizations is the focus of this bundle. Sessions include the Emerging Role of the Patient Voice on Drug Policy in Japan, Benefit Versus Risk of Harm: Assessing Therapeutic Response and Interpreting Benefit/Risk with Patients, Rare Disease Clinical Research Consortia: Immediate and Rich Sources of Translational Research Data, Partnering Opportunities; and The Cross-over Between Direct-to-patient Studies, Social Media, and EDC. For $299, learn the latest in patient recruitment.

Sessions included:
109 New Ways to Learn What Happens to Patients AFTER Approval
123 Standards for Patients: Collaborations to Innovate Therapy Development
306 Patient Advocacy and Your Next Generation of Research: How Nonprofit Organizations Can Accelerate Product Development
312 Patient Advocacy in Medical Product Development: The Evolving Relationship Between FDA and Its Patient Stakeholders
385 Emerging Role of the Patient Voice on Drug Policy in Japan
389 Benefit Versus Risk of Harm: Assessing Therapeutic Response and Interpreting Benefit/Risk with Patients
396 Rare Disease Clinical Research Consortia: Immediate and Rich Sources of Translational Research Data, Partnering Opportunities
408 The Cross-over Between Direct-to-patient Studies, Social Media, and EDC